Health Care [ 2/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform.
Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 26 | -0.32 Decreased by -9.38% | -0.35 Increased by +9.32% |
| Feb 6, 26 | -0.38 Decreased by -91.15% | -0.31 Decreased by -22.58% |
| Nov 10, 25 | -0.17 Increased by +45.69% | -0.32 Increased by +46.88% |
| Aug 6, 25 | -0.25 Decreased by -308.42% | -0.25 Decreased by -1.58% |
| May 29, 25 | -0.29 Decreased by -52.63% | -0.26 Decreased by -10.31% |
| Feb 11, 25 | -0.20 Increased by +33.73% | -0.24 Increased by +17.17% |
| Nov 12, 24 | -0.31 Increased by +21.75% | -0.26 Decreased by -20.38% |
| Aug 8, 24 | 0.12 Increased by +131.58% | -0.26 Increased by +146.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 2.52 M Decreased by -66.71% | 302.99 M Increased by +246.75% | Increased by +12.02 K% Increased by +540.82% |
| Dec 31, 25 | 2.00 M Decreased by -77.83% | -265.89 M Decreased by -256.98% | Decreased by -13.30 K% Decreased by -808.17% |
| Sep 30, 25 | 1.57 M Decreased by -64.89% | -113.52 M Increased by +50.68% | Decreased by -7.23 K% Decreased by -40.48% |
| Jun 30, 25 | 2.17 M Decreased by -72.84% | -223.35 M Decreased by -334.38% | Decreased by -10.29 K% Decreased by -962.99% |
| Mar 31, 25 | 7.57 M Decreased by -16.08% | -206.47 M Decreased by -36.63% | Decreased by -2.73 K% Decreased by -62.81% |
| Dec 31, 24 | 9.02 M Decreased by -42.05% | 169.38 M Decreased by -96.68% | Increased by +1.88 K% Decreased by -94.26% |
| Sep 30, 24 | 4.47 M Increased by +22.67% | -230.18 M Increased by +24.36% | Decreased by -5.14 K% Increased by +38.34% |
| Jun 30, 24 | 7.99 M Decreased by -63.05% | 95.30 M Increased by +132.66% | Increased by +1.19 K% Increased by +188.38% |